Terapia de Manutenção do Upadacitinib na Doença de Crohn: Resultados Finais do Estudo U-ENDURE de Fase 3 Randomizado
GastroenterologiaResumo original em inglês
O que aconteceu
Upadacitinib, an oral, reversible Janus kinase inhibitor, demonstrated efficacy and safety in patients with Crohn's disease in 2 phase III induction trials (U-EXCEL and U-EXCEED) and in a primary analysis of the first 502 patients entering the subsequent maintenance trial (U-ENDURE). Here, we present the overall results of the entire population of U-ENDURE (N = 673).
Clinical responders to 12 weeks of upadacitinib 45 mg once daily (QD) induction were randomized (1:1:1) to receive upadacitinib 15 mg QD (n = 221), upadacitinib 30 mg QD (n = 229), or placebo (n = 223) as maintenance therapy for 52 weeks. Coprimary endpoints were Crohn's Disease Activity Index (CDAI) clinical remission and endoscopic response at week 52. Safety was assessed through week 52.
gov Number: NCT03345823.
O que encontraram
At week 52, more upadacitinib-treated vs placebo patients achieved CDAI clinical remission (upadacitinib 15 mg, 36.2% and upadacitinib 30 mg, 51.5% vs placebo, 15.2%). The rates of endoscopic response were 27.3% for upadacitinib 15 mg and 40.7% for upadacitinib 30 mg vs 7.2% for placebo. Exposure-adjusted event rates for treatment-emergent adverse events were numerically lower with upadacitinib 15 mg and 30 mg vs placebo (351.3 and 324.5 per 100 patient-years, respectively, vs 462.8 per 100 patient-years) except for COVID-19 and adverse events leading to early discontinuation of study treatment. No deaths, active tuberculosis, lymphoma, nonmelanoma skin cancer, adjudicated major cardiovascular adverse events, or venous thromboembolic events were reported from any treatment group. Herpes zoster infections occurred more frequently in the upadacitinib groups compared with placebo; all were nonserious, and most involved a single dermatome.
Por que isso importa
Consistent with the primary analysis, upadacitinib was more efficacious than placebo in achieving clinical and endoscopic endpoints in patients with Crohn's disease. The safety profile remained consistent with no new safety signals.
Resumo publicado sob licença CC BY. A tradução para o português ainda não chegou a este estudo.
O estudo original
Upadacitinib Maintenance Therapy in Crohn's Disease: Final Results From the Randomized Phase 3 U-ENDURE Study
Remo Panaccione, Miguel Regueiro, Scott D Lee, Raja Atreya, Gitte Pedersen, Efrat Broide, Cristina Rodriguez, Adriaan A van Bodegraven, Elena Dubcenco, Ana P Lacerda et al.
Descritores MeSH
- Janus Kinase Inhibitors
- Crohn Disease
- Heterocyclic Compounds, 3-Ring
- Maintenance Chemotherapy
- Female
- Young Adult
- Humans
- Male
- Middle Aged
- Adult
Veja também
Estudos relacionados
- Perfil benefício-risco de upadacitinib: análise exploratória post hoc de estudos de fase 2b/3 em pacientes com colite ulcerativa moderada a grave ou doença de Crohn
- Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study
- Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study
- Upadacitinib Induction and Maintenance Therapy for Crohn's Disease